The First EASL Nonalcoholic Fatty Liver Disease (NAFLD) Summit: “Target-oriented approach to Diagnosis and Pharmacotherapy of Nonalcoholic Steatohepatitis (NASH), a dialogue between Academia and Industry” was held last week in Rome.
ProSciento´s CEO, Dr. Marcus Hompesch, presented a work in collaboration with OWL Metabolomics, describing the latest updates on the application of a non-invasive integrated biomarker screening approach (NIBS) to facilitate enrollment in clinical trials with investigational therapeutics for NAFLD/NASH.
Link:
www.easl.eu/discover/events/detail/2017/first-easl-nafld-summit-target-oriented-approach-to-diagnosis-and-pharmacotherapy-of-nash-a-dialogue-between-academia-and-industry
Download file
With this web OWL intends to provide users with information to better understand their health and their diagnosed illnesses. You should consult with aqualified physician for diagnosis and for answers to your personal questions/circunstances.Last update: 12/28/2022